Mandate

Vinge advises Aqua Dental and its current owners in connection with Novax investment

January 29, 2021 M&A

Vinge advises Aqua Dental and its current owners in connection with Novax, an investment company of the Axel Johnson Group, investment in Aqua Dental, through which Novax becomes a significant minority shareholder in the entrepreneurial company.

During the past six years, Aqua Dental has grown from 27 employees to over 400 and is thereby one of the country’s largest and fastest growing dental care chains. The company’s aim is to provide Sweden’s best and safest dental care through accessibility, passion and quality. Aqua Dental invests substantial amounts in innovation and development, with the purpose of being able to offer good dental health benefits to as many as possible. It was also the first dental chain in the country to offer digital dentist appointments.

Vinge’s team primarily consisted of Jonas Bergström, Carl Sander and Hanna Risberg (M&A) as well as Karl-Hugo Engdahl (GDPR).

Feel free to visit www.aquadental.se for further information.

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025